Z

Zevra Therapeutics Inc
NASDAQ:ZVRA

Watchlist Manager
Zevra Therapeutics Inc
NASDAQ:ZVRA
Watchlist
Price: 8.34 USD -6.92% Market Closed
Market Cap: 469.5m USD

Operating Margin
Zevra Therapeutics Inc

-34.3%
Current
-227%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-34.3%
=
Operating Profit
-29m
/
Revenue
84.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Zevra Therapeutics Inc
NASDAQ:ZVRA
468.9m USD
-34%
US
Eli Lilly and Co
NYSE:LLY
978.2B USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
485.6B USD
27%
CH
Roche Holding AG
SIX:ROG
257.9B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
206.8B GBP
24%
US
Merck & Co Inc
NYSE:MRK
265B USD
38%
CH
Novartis AG
SIX:NOVN
207.5B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.5T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
142.8B USD
29%
No Stocks Found

Zevra Therapeutics Inc
Glance View

Zevra Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company, which engages in the discovery and development of proprietary prodrugs. The company is headquartered in Celebration, Florida and currently employs 36 full-time employees. The company went IPO on 2015-04-16. The firm is engaged in creating therapies for diseases with limited or no treatment options. The firm has a diverse portfolio of products and product candidates, which includes a combination of both a clinical-stage pipeline and commercial stage assets. The company employs its LAT platform technology to create a portfolio of approved products. Its product candidates include Arimoclomol, KP1077IH, KP1077N and AZSTARYS. Arimoclomol is an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate, which is being developed as a treatment for idiopathic hypersomnia (IH) and narcolepsy. KP1077 is comprised solely of serdexmethylphenidate (SDX), the Company's prodrug of d-methylphenidate (d-MPH). AZSTARYS is a prodrug for the treatment of ADHD in patients aged six years or older.

ZVRA Intrinsic Value
25.15 USD
Undervaluation 67%
Intrinsic Value
Price
Z
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-34.3%
=
Operating Profit
-29m
/
Revenue
84.4m
What is the Operating Margin of Zevra Therapeutics Inc?

Based on Zevra Therapeutics Inc's most recent financial statements, the company has Operating Margin of -34.3%.

Back to Top